Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
Jim Cramer Says He's Known Novavax Is 'Worthless' For 'Very Long Time,' Trashes Company For Being Too 'Promotional'
06:21pm, Wednesday, 01'st Mar 2023 Benzinga
Novavax Inc (NASDAQ: NVAX) shares are crashing Wednesday after the company warned that substantial doubt exists regarding its ability to continue.
Jim Cramer isn't surprised.
"I've been saying the
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
09:51pm, Tuesday, 28'th Feb 2023 The Motley Fool
It's not a good day for investors when their company reports a shocking plunge into the red.
Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates
05:05pm, Tuesday, 28'th Feb 2023 Zacks Investment Research
Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
04:51pm, Tuesday, 28'th Feb 2023
It's not a good day for investors when their company reports a shocking plunge into the red.
Wall Street Analysts Believe Emergent Biosolutions (EBS) Could Rally 134.29%: Here's is How to Trade
02:55pm, Tuesday, 28'th Feb 2023 Zacks Investment Research
The consensus price target hints at a 134.3% upside potential for Emergent Biosolutions (EBS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates
01:33pm, Tuesday, 28'th Feb 2023
Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.
Emergent BioSolutions (EBS) Q4 2022 Earnings Call Transcript
03:00am, Tuesday, 28'th Feb 2023 The Motley Fool
EBS earnings call for the period ending December 31, 2022.
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
11:55pm, Monday, 27'th Feb 2023 Zacks Investment Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -196.88% and 7.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc
Emergent BioSolutions Inc. (EBS) Q4 2022 Earnings Call Transcript
11:01pm, Monday, 27'th Feb 2023
Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President and CE
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
09:42pm, Monday, 27'th Feb 2023 GlobeNewswire Inc.
GAITHERSBURG, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2022.
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
08:19pm, Monday, 27'th Feb 2023
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -196.88% and 7.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc
Fulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
03:00pm, Thursday, 23'rd Feb 2023 Zacks Investment Research
Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Beat Estimates
01:55pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 87.04% and 0.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead
Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for
03:00pm, Monday, 20'th Feb 2023 Zacks Investment Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent BioSolutions: Positive NARCAN FDA Panel, Divesting Travel Health, Raising Rating To Buy
06:27am, Sunday, 19'th Feb 2023
Emergent BioSolutions has shown a remarkable turnaround since challenging Q3:22 results with a $380 million procurement contract and restructuring plan. Now, a definitive step toward a NARCAN over-the
